CDC Warns Drug-Resistant Germs Cause Nearly 10 Million US Infections a Year in New 2026 Report

The CDC drug-resistant germs 2026 report has put a stark new estimate at the centre of American public health debate. The United States Centers for Disease Control and Prevention says drug-resistant bacteria and fungi now account for about 9.7 million infections and roughly 50,800 deaths in the United States each year. Those figures, drawn from 2023 data, form the core of the agency’s 2026 Antimicrobial Resistance Threats Report, released on October 27, 2026, and described as its most comprehensive assessment since 2019.

The report does not claim that every infection is untreatable, and it does not claim that the danger is evenly spread. It sorts 19 pathogens into tiers of concern, separates a small group that demands urgent and aggressive action from a larger group that requires prompt and sustained action, and adds a watch list of six more germs whose full burden is not yet understood. For patients, hospitals and policymakers, the message is therefore twofold: progress in some areas is real, but resistance is still spreading in ways that make ordinary care harder, longer and more expensive.

What the CDC Reported This Week

The Headline Numbers

The headline numbers are deliberately presented as annual estimates rather than a precise count of every case. The CDC puts drug-resistant infections at about 9.7 million a year, with some summaries rounding the same estimate to 9.8 million, and deaths at approximately 50,800 a year. Infections commonly associated with health care account for more than 42,000 of those deaths, and the health-care cost attached to those infections is put at nearly 12 billion dollars. Those two details matter because they shift the story away from an abstract national total and toward wards, clinics and long-term care settings where vulnerable people are most exposed.

It is worth pausing on what an annual estimate means in practice. A single resistant infection can mean a longer hospital stay, a switch to a second or third drug, isolation precautions for the patient, and extra testing for contacts. Multiplied across millions of cases, even small delays in effective treatment add up to the cost and mortality figures in the report. The CDC is not describing a single outbreak. It is describing a background burden that is present every day, in every state, even when no single hospital makes the news.

Why This Report Is Different

This is the first full threats report of its kind since 2019, and the agency stresses that its methods and data sources have been updated. That update is important for anyone tempted to draw a straight line from the older figures to the new ones. The 2019 report, based on 2013 data, estimated more than 2.8 million resistant infections and more than 35,000 deaths a year. The new report is broader, counts more kinds of infection, and draws on more surveillance systems, so the CDC cautions against treating the difference between the two totals as a simple measure of growth.

The agency assessed threats using seven factors, including clinical impact, economic impact, the current number of new infections, the projected change over the next five years, transmissibility, preventability, and whether effective antibiotics or antifungals are available. That framework explains why two germs with similar case counts can sit in different tiers: one may be containable with existing hygiene and stewardship, while another may have almost no reliable treatment left. The ranking is therefore a judgement about urgency, not just a league table of size.

The Four Urgent Threats

Candida Auris, the Fungus That Spreads in Hospitals

At the top of the urgent list sits Candida auris, a yeast-like fungus now also referred to as Candidozyma auris. The CDC says it was first detected in American hospitals about ten years ago, yet it caused 4,523 infections in 2023, roughly a tenfold increase since 2019. The fungus is often found on patients’ skin, spreads rapidly in health-care settings, and affects some of the most vulnerable patients, including people already seriously ill or with long hospital stays.

Treatment is the core difficulty. The fungus is described as almost completely resistant to one class of antifungal medicines, with emerging resistance to the other two classes. Resistant infections are reported to be fatal in between 29 percent and 62 percent of patients in the figures cited by specialists discussing the report, a wide range that reflects how sick the affected patients already are as well as the limits of the drugs available. Former CDC mycotic diseases chief Tom Chiller has argued that the response needs both more drug development and practical measures: working out how to decolonise patients, disinfecting health-care environments rapidly, and screening patients and settings far more widely.

Carbapenem-Resistant Bacteria and Drug-Resistant Gonorrhoea

The other urgent threats are carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales, known as CRE, and drug-resistant gonorrhoea. Carbapenems are a class of antibiotics often reserved for serious infections, so resistance to them removes one of the last reliable options. CRE in particular is described as a family of multidrug-resistant bacterial pathogens that have become increasingly difficult to treat and that can share their resistance with other bacteria, a feature that makes containment harder than a single strain outbreak.

These bacteria pose the greatest threat to hospital patients, especially people with indwelling devices such as ventilators and catheters, where bacteria can gain a foothold and where infection control must be constant. A study cited in coverage of the report found CRE incidence at American hospitals increased by 18 percent from 2019 to 2023. Drug-resistant gonorrhoea, meanwhile, shows why the problem is not confined to hospitals: a common sexually transmitted infection is becoming harder to cure with standard treatment, which raises the stakes for testing, partner notification and follow-up even outside a ward.

The Serious and Concerning Lists

What Serious Means in Practice

Thirteen pathogens are classed as serious threats, meaning they require prompt and sustained action, while two are classed as concerning, meaning they require careful monitoring and prevention action. The distinction is not a reassurance. A serious threat can still cause large numbers of infections, still complicate surgery, cancer care and childbirth, and still become urgent if resistance spreads or treatment options narrow further. The tiers are a call to act at different speeds, not a division between dangerous and safe.

Among the changes in this edition, drug-resistant Neisseria meningitidis has been added as a serious threat. Meningococcal disease is uncommon but can become severe very quickly, so adding a resistant form to the serious list signals that clinicians and public health teams should watch for treatment failures and keep vaccination and rapid diagnosis at the forefront. The report’s value here is less in any single new name and more in the way it forces health systems to prioritise: which germs get extra surveillance, which get stewardship attention, and which get research funding first.

What Changed Since the Last Report

One of the clearest changes is also one of the few encouraging ones. Clostridioides difficile, often called C. diff, a bacterium that can cause serious and sometimes deadly diarrhoea, has been moved down from urgent to serious after a decline in rates. Its rates began to fall in 2018 and have remained stable since 2020, a pattern the CDC links in part to successful infection prevention actions, especially in health-care settings. That downgrade does not mean C. diff has disappeared, but it does suggest that sustained hygiene, cleaning and antibiotic stewardship in hospitals can bend a curve.

Other movements point the other way, and the report is frank about them. Resistance genes, including genes that confer resistance to prized antibiotics, are spreading widely between bacteria, so a resistance trait first seen in one organism can appear in another. That gene-sharing is one reason the CDC treats CRE and related bacteria as urgent even when a single hospital’s case count looks modest. The threat is not only the germ in front of a clinician today, but the genetic toolkit it may pass on tomorrow.

The Watch List and the Germs Being Watched

Six Pathogens Under Monitoring

Beyond the 19 ranked threats, the CDC includes a watch list of six additional pathogens currently being monitored because their full burden is not yet understood. The watch list is a deliberate middle ground: not a warning that each germ is already a major killer, and not a dismissal either. It is a statement that surveillance is incomplete, that early signals deserve attention, and that a germ can move up the tiers if new data show a larger impact or faster spread.

Three pathogens were added to the watch list in this edition: drug-resistant dermatophytes, drug-resistant Haemophilus influenzae, and nontuberculous mycobacteria. Dermatophytes are fungi that commonly cause skin, hair and nail infections, so a resistant form matters for everyday dermatology as well as for people with weakened immune systems. Haemophilus influenzae can cause ear, lung and more serious invasive disease, while nontuberculous mycobacteria are environmental bacteria that can cause persistent lung infections, particularly in people with existing lung conditions.

Why a Watch List Matters

A watch list matters because antimicrobial resistance rarely announces itself with a single dramatic event. It builds through small changes: a drug that used to work in three days now takes five, a standard dose fails and a second drug is needed, a patient who would once have gone home stays for extra observation. By naming germs before their burden is fully quantified, the CDC gives laboratories a reason to test for them, hospitals a reason to record them consistently, and researchers a reason to study them before they become entrenched.

For the public, the watch list is also a reminder that the 19 ranked threats are not the whole story. The report’s headline total counts infections from the ranked pathogens, while the watch list points to the next set of questions: how common are these germs, who do they harm most, and do current drugs still work reliably against them? If those questions are answered late, the eventual response is likely to be more expensive and less effective than early monitoring would have been.

Hospitals at the Centre of the Burden

The Health-Care Share of Deaths and Costs

Health-care-associated infections dominate the mortality and cost figures in the report. More than 42,000 of the estimated 50,800 annual deaths are linked to infections commonly associated with health care, and those infections carry nearly 12 billion dollars in health-care costs. That concentration is not surprising once the setting is considered: hospitals bring together people who are already ill, invasive devices, shared equipment, antibiotics used at high intensity, and staff moving between patients under time pressure.

The cost figure, like the death figure, should be read as an estimate of burden rather than a bill for a single item. It captures longer stays, extra drugs, isolation, repeat testing and the downstream care that follows a resistant infection. For a health system already under strain, that burden competes directly with other priorities: beds that cannot be freed, staff time that cannot be redeployed, and budgets that must absorb treatment that might have been shorter and simpler if the first drug had worked.

How Resistance Spreads in Wards

Resistance spreads in wards through routes that are ordinary rather than exotic. Hands, surfaces, shared devices and the movement of patients between units can all carry bacteria and fungi from one person to another, especially when a germ can live on skin or on equipment without causing immediate symptoms. Candida auris is a vivid example because it can colonise skin and persist in the environment, which is why rapid disinfection and screening are repeatedly emphasised by specialists.

Antibiotic use itself is part of the dynamic. Every course of antibiotics creates selection pressure: susceptible bacteria die, while any resistant survivors have more room to grow. That does not mean antibiotics should be avoided when they are needed. It means the decision to start, continue or stop a course matters beyond the individual patient, and that hospitals need systems — stewardship teams, prescribing review, and infection prevention staff — that can make those decisions consistently rather than leaving them to habit or urgency alone.

Why the Numbers Look Larger Than in 2019

Method Changes Behind the New Totals

The CDC is explicit that the new totals cannot be compared directly with the 2019 report, and the reasons are concrete rather than technical fine print. Group A and group B streptococci were previously counted only when infections were invasive, while the new report also includes non-invasive infections. For C. difficile, the old report counted only hospitalised patients, while the new report adds non-hospitalised cases. Expanding the net in those ways inevitably raises the counted total, even if the underlying risk for a given patient had not changed at all.

That caution cuts both ways. It would be wrong to claim that resistance has suddenly tripled in a few years on the basis of these two reports alone, because the counting rules changed. It would be equally wrong to dismiss the new figures as an artefact, because the CDC also says increases are real in several pathogens, particularly health-care-associated infections. The honest reading is that the new report gives a fuller picture of a large and growing problem, while the exact pace of growth for each germ needs the pathogen-by-pathogen detail inside the report rather than a single headline comparison.

What Is Genuinely Rising

Within that fuller picture, several rises stand out and are not explained by counting changes alone. Candida auris infections rose about tenfold since 2019, to 4,523 cases in 2023, a trajectory that specialists describe as a genuine surge in health-care settings. CRE incidence at American hospitals rose 18 percent between 2019 and 2023, and resistance genes such as NDM, which can confer resistance to carbapenems, are reported to be spreading rapidly. Those patterns point to transmission and gene-sharing, not just better detection.

At the same time, the C. difficile story shows that a rise is not inevitable. Rates fell from 2018 and stabilised after 2020, and the pathogen was downgraded accordingly. Taken together, the two patterns tell a coherent story: where prevention, cleaning and stewardship are sustained, a resistant germ can be pushed back, and where screening, disinfection and drug development lag, a germ can spread quickly. The report’s overall tone — progress made, significant work remaining — follows directly from that contrast.

What This Means for Patients and Families

Everyday Risk, Not Just Hospital Risk

For most people, the everyday risk from a drug-resistant germ is not that a routine cut will suddenly become untreatable, but that treatment for a future illness, operation or childbirth complication may be less straightforward than expected. Modern medicine depends heavily on reliable antibiotics and antifungals: they protect surgical patients, support cancer treatment, make organ transplantation possible, and treat infections that would otherwise spread. When those drugs lose reliability, the safety margin around all of that care narrows.

That dependence is why CDC Director Dr Erica Schwartz framed the issue in broad terms, saying antimicrobial resistance threatens modern medicine and puts millions of Americans at risk every year, while also noting both the progress made and the significant work that remains. The statement is not a prediction that antibiotics will stop working altogether. It is a warning that the foundation on which much of modern care rests is eroding, and that erosion will show up first in the patients who can least afford a delay: newborns, older adults, people with weakened immune systems, and people already in hospital.

When the First Drug Does Not Work

When the first drug does not work, the consequences are practical before they are dramatic. A patient may need a different drug, a higher dose, an intravenous treatment instead of tablets, a longer stay, or a transfer to a specialist unit. Each step adds risk, discomfort and cost, and each step depends on laboratory testing that can identify the germ and its resistance pattern quickly. Delayed identification is therefore part of the harm, not just a footnote to it.

Patients and families can reduce risk in ordinary ways that do not require medical expertise: keeping hands clean, following wound-care and discharge instructions, attending follow-up appointments, and asking clinicians whether an antibiotic is needed and, if so, what to expect. Public health guidance consistently emphasises not pressing for antibiotics for illnesses that are viral, and completing a prescribed course as directed rather than stopping early or sharing leftover medicine. Those steps do not solve resistance on their own, but they slow the selection pressure that drives it, and they protect the next patient as well as the current one.

What Comes Next After the Report

Prevention, Stewardship and Surveillance

The report’s implicit prescription is not a single new drug but a system: better infection prevention in hospitals and care homes, steadier antibiotic stewardship, and broader genomic surveillance that can track resistance genes as they move between bacteria. Infectious Diseases Society of America President Dr Wendy Armstrong called the numbers alarming by any measure, adding that they are particularly sobering when clinicians connect real patients with the statistics in everyday practice. That reaction captures why specialists are pressing for action that is sustained rather than episodic.

Prevention in this context is unglamorous work: hand hygiene, environmental cleaning, isolation precautions, device care, and screening of high-risk patients and settings. Stewardship is equally practical: reviewing prescriptions, stopping drugs that are no longer needed, choosing narrower drugs when they will work, and reserving the broadest drugs for cases that truly require them. Surveillance ties the two together, because without consistent testing and reporting, a hospital cannot know whether its own resistance pattern is improving or worsening, and a country cannot know where to send help first.

New Drugs, Funding and the PASTEUR Act

Drug development is the other half of the response, and it is the half that specialists say is currently weakest. Developing a new antibiotic or antifungal is scientifically difficult and commercially unattractive, because a good new drug should be used sparingly to preserve its effectiveness, which limits sales. Public health and medical groups cited in coverage of the report therefore point to financial incentives, including proposals such as the PASTEUR Act, as a way to revive development without encouraging overuse.

Whether that legislation advances, and in what form, is not settled in the report itself, and the report does not promise a pipeline of new drugs on any particular timetable. What it does establish is the scale of the need: 19 ranked threats, six more under watch, millions of infections a year, and a small group of urgent threats for which treatment options are already thin. For policymakers, the question after this report is less whether resistance matters and more how quickly prevention, surveillance and incentives can be funded at a level that matches a burden of nearly ten million infections a year.

The 2026 report should therefore be read as a fuller and more honest count, not as a reason for panic and not as a reason for complacency. It shows a burden that is large, concentrated in health care, and still growing for several important germs, while also showing that sustained prevention can move a pathogen down the threat list. The work that remains is the unglamorous, continuous work of cleaning, testing, prescribing carefully and developing new drugs — done consistently enough that the next report can show more downgrades than upgrades.

Comments

comments